<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02314026</url>
  </required_header>
  <id_info>
    <org_study_id>NASH-EX-1114</org_study_id>
    <nct_id>NCT02314026</nct_id>
  </id_info>
  <brief_title>BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH</brief_title>
  <official_title>Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exalenz Bioscience LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exalenz Bioscience LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study's aim is to develop an algorithm for the ¹³C-Octanoate Breath Test with or without
      the ¹³C-Methacetin Breath Test (OBT and MBT respectively) for correlation with histological
      findings associated with of Non-Alcoholic Steatohepatitis (NASH) and other liver diseases
      using the BreathID® System
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-Alcoholic Steatohepatitis (NASH) is a growing epidemic in the western world due to the
      contemporary eating habits and life styles.NASH can lead to cirrhosis, hepatic carcinoma and
      other liver complications. There are currently some treatments available. The only definitive
      way of detecting NASH in patients with advanced liver disease is by liver biopsy. However,
      liver biopsy has disadvantages, such as sampling errors, chance of complications and does not
      lend itself to following up after treatment.

      A non-invasive test that could potentially replace biopsy and aid in NASH detection and
      treatment monitoring, would improve management of suspected NASH patients without the need
      for biopsy. This protocol will obtain the results of one or two different breath tests to
      provide an accurate evaluation of the liver status in patients at high risk for NASH.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Biopsy Proven Non-Alcoholic Steatohepatitis</measure>
    <time_frame>30 days</time_frame>
    <description>Non-Alcoholic Steatohepatitis (NASH) as determined by liver biopsy histology will be the comparator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver Decompensation as Measured by Area Under Receiver Operating Curve</measure>
    <time_frame>36 months</time_frame>
    <description>Observe if breath tests correlate to clinical outcome of liver decompensation, including ascites, variceal bleeding, hepatic encephalopathy and spontaneous bacterial peritonitis.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>48 hours from last breath test</time_frame>
    <description>A phone call will be made to each subject 48 hours after the last breath test to confirm that no adverse events related to breath test have been experienced.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Non-Alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Suspected NASH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13C-Octanoate, 13C-Methacetin</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Suspected NASH BreathID test with 13C-Octanoate</intervention_name>
    <description>Subject will have breath measured before and after ingestion of solution of 100 mg 13C Octanoate dissolved in 150 cc of water</description>
    <arm_group_label>Suspected NASH</arm_group_label>
    <other_name>Sodium Octanoate breath test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Suspected NASH Breath test with 13C Methacetin</intervention_name>
    <description>Subject will have breath measured before and after ingestion of solution of 75 mg 13C Methacetin dissolved in 150 cc of water</description>
    <arm_group_label>Suspected NASH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult men or women (≥18 years of age)

          2. Liver biopsy, indicating NAFLD/NASH, performed within 6 months prior to both breath
             tests OR undergoing liver biopsy to rule-out or confrim NAFLD/NASH. NOTE:The samples
             obtained meet defined quality criteria. (In Appendix II of protocol)

          3. Any elevation of liver enzymes above the upper limit of normal (any or all of the
             following: AST, ALT, GGT, Alkaline phosphatase) for at least 3 months

          4. No other known co-existent liver disease, excluded by appropriate serologic / other
             testing

          5. Imaging - US / CT / MRI (if available) with the typical image of Fatty Liver or
             suggestive of NASH.

          6. Patient (or legal guardian) able and willing to sign an Informed Consent Form

          7. Can tolerate an overnight (8-hour) fast

        Exclusion Criteria:

          1. Positive studies for any of the following within three years prior to biopsy:

               1. Anti HCV positive

               2. Anti HB core antibody positive

               3. Iron saturation &gt; 60% + gene test for hereditary hemochromatosis or iron overload
                  as defined by presence of 3+ or 4+ stainable iron on liver biopsy

               4. Antinuclear antibody at a titer &gt; 1: 160 along with hypergammaglobulinemia and 5
                  times ALT normal levels

               5. Alpha-1-antitrypsin level below lower limit of normal (&lt; 150 mg/dl) or no PAS
                  diastase resistant globules on biopsy.

               6. Primary biliary cirrhosis as defined by elevation of alkaline phosphatase greater
                  than upper limit of normal and anti-mitochondrial antibody (AMA) of greater than
                  1:80 and consistent liver histology

               7. Low level of ceruloplasmin

               8. Drug-induced liver disease as defined on the basis of typical exposure and
                  history

          2. Patients known to have chronic liver disease other than NAFLD as routinely diagnosed
             by the investigator

          3. Concurrent acute hepatic condition other than NAFLD

          4. Alcohol consumption &gt; 20 gm/day (0.71 oz/day) for women and &gt; 30 gm/day (1.06 oz/day)
             for men

          5. Drugs that may interfere with octanoate metabolism or can also cause NAFLD independent
             of the metabolic syndrome, including: corticosteroids, amiodarone, tetracycline,
             valproic acid, methotrexate, stavudine, zidovudine

          6. When MBT is performed subject should not have taken any of the following at least 48
             hours prior to the breath test: Acyclovir , allopurinol, carbamazepine, cimetidine,
             ciprofloxacin, daidzein, (herbal) disulfiram, echinacea, enoxacin, famotidine,
             fluvoxamine, methoxsalen, mexiletine, montelukast, norfloxacin, phenylpropanolamine,
             phenytoin, propafenone, rifampin, terbinafine, ticlopidine, thiabendazole, verapamil,
             zileuton or any medication that might interfere with Methacetin metabolism or might
             affect CYP 1A2

          7. Patients that have had more than 10% weight change between biopsy and enrollment.

          8. Hypersensitivity to any of the study substrates; i.e. Octanoate or Methacetin
             respectively

          9. Known extra-hepatic diseases including but not limited to: severe congestive heart
             failure (NIHA&gt;2), known severe pulmonary hypertension (&gt;35 mmHg), history of chronic
             obstructive pulmonary disease or uncontrolled symptomatic bronchial asthma or
             uncontrolled diabetes mellitus (HA1c&gt;9.5%)

         10. Previous surgical GI bypass surgery

         11. Extensive small bowel resection (&gt;100 cm)

         12. Known uncontrolled malabsorption or diarrhea

         13. Concurrent total parenteral nutrition

         14. Any organ transplant

         15. Patients receiving any anti-viral treatment or any other liver directed therapy,
             procedure or surgery between the time of the biopsy and the breath test

         16. Pregnant or breast feeding

         17. Patients and/or legal guardian unable or refusing to sign informed consent

         18. Patients that, based on the opinion of the investigator, should not be enrolled into
             this study due to safety / adherence reasons.

         19. Patients participating in other clinical trials and already receiving experimental
             treatments or procedures

         20. Patients with suspected or documented hepatocellular carcinoma by ultra-sound or other
             imaging modality

         21. Patients diagnosed with partial / complete portal venous occlusion, hepatic venous
             occlusion, previous PHT surgery, or placement of a transjugular intrahepatic
             portosystemic shunt (TIPS) according to initial imaging studies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaron Ilan, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University, Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Military Medical Center</name>
      <address>
        <city>Forts Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Immaculate Hospital</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital (UZA)</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>New Castle</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 4, 2014</study_first_submitted>
  <study_first_submitted_qc>December 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2014</study_first_posted>
  <results_first_submitted>February 7, 2019</results_first_submitted>
  <results_first_submitted_qc>February 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 19, 2019</results_first_posted>
  <last_update_submitted>February 27, 2019</last_update_submitted>
  <last_update_submitted_qc>February 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT02314026/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Suspected NASH</title>
          <description>13C-Octanoate, 13C-Methacetin
Suspected NASH BreathID test with 13C-Octanoate: Subject will have breath measured before and after ingestion of solution of 100 mg 13C Octanoate dissolved in 150 cc of water
Suspected NASH Breath test with 13C Methacetin: Subject will have breath measured before and after ingestion of solution of 75 mg 13C Methacetin dissolved in 150 cc of water</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Suspected NASH</title>
          <description>13C-Octanoate, 13C-Methacetin
Suspected NASH BreathID test with 13C-Octanoate: Subject will have breath measured before and after ingestion of solution of 100 mg 13C Octanoate dissolved in 150 cc of water
Suspected NASH Breath test with 13C Methacetin: Subject will have breath measured before and after ingestion of solution of 75 mg 13C Methacetin dissolved in 150 cc of water</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="135"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.4" spread="12.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Biopsy Proven Non-Alcoholic Steatohepatitis</title>
        <description>Non-Alcoholic Steatohepatitis (NASH) as determined by liver biopsy histology will be the comparator</description>
        <time_frame>30 days</time_frame>
        <population>Subjects that had a valid biopsy and performed both Octanoate and Methacetin Breath test</population>
        <group_list>
          <group group_id="O1">
            <title>Suspected NASH</title>
            <description>13C-Octanoate, 13C-Methacetin
Suspected NASH BreathID test with 13C-Octanoate: Subject will have breath measured before and after ingestion of solution of 100 mg 13C Octanoate dissolved in 150 cc of water
Suspected NASH Breath test with 13C Methacetin: Subject will have breath measured before and after ingestion of solution of 75 mg 13C Methacetin dissolved in 150 cc of water</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Biopsy Proven Non-Alcoholic Steatohepatitis</title>
          <description>Non-Alcoholic Steatohepatitis (NASH) as determined by liver biopsy histology will be the comparator</description>
          <population>Subjects that had a valid biopsy and performed both Octanoate and Methacetin Breath test</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Definite NASH</title>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Probable NASH</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Absent of NASH</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Liver Decompensation as Measured by Area Under Receiver Operating Curve</title>
        <description>Observe if breath tests correlate to clinical outcome of liver decompensation, including ascites, variceal bleeding, hepatic encephalopathy and spontaneous bacterial peritonitis.</description>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Suspected NASH</title>
            <description>13C-Octanoate, 13C-Methacetin
Suspected NASH BreathID test with 13C-Octanoate: Subject will have breath measured before and after ingestion of solution of 100 mg 13C Octanoate dissolved in 150 cc of water
Suspected NASH Breath test with 13C Methacetin: Subject will have breath measured before and after ingestion of solution of 75 mg 13C Methacetin dissolved in 150 cc of water</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Decompensation as Measured by Area Under Receiver Operating Curve</title>
          <description>Observe if breath tests correlate to clinical outcome of liver decompensation, including ascites, variceal bleeding, hepatic encephalopathy and spontaneous bacterial peritonitis.</description>
          <units>Probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.852" lower_limit="0.771" upper_limit="0.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Adverse Events</title>
        <description>A phone call will be made to each subject 48 hours after the last breath test to confirm that no adverse events related to breath test have been experienced.</description>
        <time_frame>48 hours from last breath test</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Suspected NASH</title>
            <description>13C-Octanoate, 13C-Methacetin
Suspected NASH BreathID test with 13C-Octanoate: Subject will have breath measured before and after ingestion of solution of 100 mg 13C Octanoate dissolved in 150 cc of water
Suspected NASH Breath test with 13C Methacetin: Subject will have breath measured before and after ingestion of solution of 75 mg 13C Methacetin dissolved in 150 cc of water</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>A phone call will be made to each subject 48 hours after the last breath test to confirm that no adverse events related to breath test have been experienced.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Possibly related adverse event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No possibly related reported adverse events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for up to 36 months from enrollment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Suspected NASH</title>
          <description>13C-Octanoate, 13C-Methacetin
Suspected NASH BreathID test with 13C-Octanoate: Subject will have breath measured before and after ingestion of solution of 100 mg 13C Octanoate dissolved in 150 cc of water
Suspected NASH Breath test with 13C Methacetin: Subject will have breath measured before and after ingestion of solution of 75 mg 13C Methacetin dissolved in 150 cc of water</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute cholecystitis</sub_title>
                <description>Acute cholecystitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Patient suffered from abdominal pain and cramping</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Patient suffered from nausea on day of test</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Patient suffered from dizziness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Patient suffered from headache on day of test</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical trial manager</name_or_title>
      <organization>Exalenz Bioscience</organization>
      <phone>97289737513</phone>
      <email>avrahamh@exalenz.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

